There is increasing evidence to suggest that CAFs may provide a specialised niche for cancer stem cells and influence responsiveness to chemotherapy in TNBC [5,15,16] and endocrine therapy in ER+ disease [17,18], supported by more recent single cell sequencing studies identifying specific subtypes of CAFs in mouse and human breast tumours [14,19]. The gene discussed is ESR1; the disease is breast neoplasm.